Overview

A Neoadjuvant Study of Abemaciclib (LY2835219) in Postmenopausal Women With Hormone Receptor Positive, HER2 Negative Breast Cancer

Status:
Completed

Trial end date:
2018-02-12

Target enrollment:

Participant gender:

Summary

The purpose of this study is to evaluate the biological effects of abemaciclib in combination with anastrozole and compare those to the effects of abemaciclib alone and anastrozole alone in the tumors of postmenopausal women with hormone receptor positive (HR+), human epidermal growth factor receptor 2 (HER2) negative breast cancer.

Phase:

Phase 2

Details

Lead Sponsor:

Eli Lilly and Company

Treatments:

Anastrozole
Antidiarrheals
Hormones
Loperamide